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Background: We performed dosimetric comparisons between proton beam therapy and intensity modulated
radiotherapy (IMRT) of intracranial germ cell tumors (ICGCTs) arising in various locations of the brain.
Materials: IMRT, passively scattered proton therapy (PSPT), and spot scanning proton therapy (SSPT) plans were
performed for four different target volumes: the whole ventricle (WV), pineal gland (PG), suprasellar (SS), and basal
ganglia (BG). Five consecutive clinical cases were selected from the patients treated between 2011 and 2014 for
each target volume. Total 20 cases from the 17 patients were included in the analyses with three overlap cases
which were used in plan comparison both for the whole ventricle and boost targets. The conformity index,
homogeneity index, gradient index, plan quality index (PQI), and doses applied to the normal substructures of the
brain were calculated for each treatment plan.
Results: The PQI was significantly superior for PSPT and SSPT than IMRT for ICGCTs in all locations (median; WV:
2.89 and 2.37 vs 4.06, PG: 3.38 and 2.70 vs 4.39, SS: 3.92 and 2.49 vs 4.46, BG: 3.01 and 2.49 vs 4.45). PSPT and SSPT
significantly reduced the mean dose, and the 10 and 15 Gy dose volumes applied to the normal brain compared
with IMRT (p ≤ 0.05). PSPT and SSPT saved significantly greater volumes of the temporal lobes and hippocampi
(p < 0.05) in the SS and PG targets than IMRT. For tumors arising in the BG, PSPT and SSPT also saved greater
volumes of the contralateral temporal lobes.
Conclusions: PSPT and SSPT provide superior target volume coverage and saved more normal tissue compared
with IMRT for ICGCTs in various locations. Future studies should assess whether the extent of normal tissue saved
has clinical benefits in children with ICGCTs.
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Intracranial germ cell tumors (ICGCTs) include tumors
of various histologic subtypes that arise from the primor-
dial germ cell of developing embryos. They are rare in
western countries, accounting for 0.5–3 % of childhood
brain tumors. However, their incidence is higher in Taiwan,* Correspondence: jooyoungcasa@ncc.re.kr
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all brain tumors in children aged < 19 years [1–3].
Although chemotherapy is widely used with the aim of
reducing radiotherapy volume, the focal radiation field
in combination with chemotherapy before radiotherapy
actually increase the risk of local and regional recurrence
[4]. The current consensus for treating localized ICGCTs
involves delivery of radiotherapy to a sufficient target of
the entire ventricular space, irrespective of the use of
chemotherapy [4–8]. However, there are concerns about
the potential adverse effects of applying radiotherapy to
a large volume on long-term neurocognitive effects andle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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most children were intact after treatment even if they re-
ceived craniospinal irradiation [9], another study showed
that there were significant declines over time in working
memory and processing speed [10]. In a Japanese study
[11], among 34 patients of University of Niigata with
intracranial germinoma who were older than 19 at the
time of follow-up, only 18 (52 %) patients had jobs in or-
dinary (unsheltered) work places and 8 (24 %) patients
were unemployed at the time of follow-up.
Because disease-related morbidities and treatment-
related complications are the major contributors to the
long-term decline in brain function, it is important to
minimize the relative dose and volume of the normal tis-
sue to those of target tissue without compromising the
treatment outcome. Proton beam therapy (PBT) is an
important radiotherapeutic modality that may improve
the neurocognitive outcomes of children with brain tu-
mors because of its dosimetric advantage compared with
other modalities [12–14]. PBT can deliver a lower radi-
ation dose to normal tissues proximal and distal to tu-
mors owing to unique depth dose distribution.
A previous study that examined the relationship be-
tween radiation dose and cognitive effects suggested that
applying low doses to subvolumes of the brain and the
reduced mean dose of proton beam therapy would trans-
late into long-term clinical advantages in several com-
mon brain tumors [15]. It was also demonstrated that
increasing the radiotherapy dose applied to the hippo-
campus and temporal lobes is associated with a greater
decline in neurocognitive skills following cranial irradi-
ation [16]. In this study, we evaluated whether PBT offers
dosimetric benefits over intensity modulated radiotherapy
(IMRT) for the treatment of ICGCTs arising in various lo-
cations of the brain with 20 ICGCT cases selected from
the single institutional database.
Methods
Patients and treatment targets
Between April 2007 and February 2014, a total of 50 pa-
tients with ICGCTs were treated at the National Cancer
Center, Korea. Passively scattered proton beam, i.e. double
scattering technique, was used to treat 36 patients with
ICGCTs. Seventeen consecutive patients with localized
ICGCTs were included in this study. The two patients
with pineal tumor and one with suprasellar tumor were
given WVI before boosting the primary site. These three
cases were used for comparing plans of both the WVI and
primary site irradiation.
All patients received four cycles of chemotherapy be-
fore radiotherapy according to the treatment scheme
proposed by the Korean Society for Pediatric Neuro-
Oncology. Regarding radiotherapy, WVI of 19.8 Gy was
given initially, and the field was reduced to the primarysite and was given 30.6–39.6 Gy, depending on the tu-
mor’s response to chemotherapy. All patients with non-
germinomatous germ cell tumors (NGGCT) received
craniospinal irradiation (CSI) of 36 Gy and the primary
site was irradiated with 55.8–59.4 Gy depending on the
tumor’s response to chemotherapy.
Treatment planning
The treatment plans were compared to investigate the
effectiveness of PBT. Brain CT images were obtained
with slice thickness of 2.5 mm using a Q-fix patient
support (Q-Fix, Avondale, PA, USA). For all patients,
the treatment targets and normal intracranial structures,
including normal brain, brainstem, temporal lobe, hippo-
campus, cochlea, lens, optic nerve, optic chiasm, hypo-
thalamus, and pituitary gland, were contoured by single
radiation oncologist using the Eclipse® treatment plan-
ning system (TPS) v10.0.2 (Varian Medical Systems, Palo
Alto, CA, USA). For target contouring, MRI was per-
formed at the same time as planning CT (after complet-
ing chemotherapy) and at the time of diagnosis (before
starting chemotherapy), and data were anatomically
registered with the planning CT. The WV gross tumor
volume (GTV) included the lateral, third, and fourth
ventricles, and the prepontine cistern. The WV clinical
target volume (CTV) was defined as the WV GTV +
0.7 cm and the WV PTV was defined as the CTV +
0.3 cm. The tumor bed GTV was contoured based on the
volume measured before chemotherapy for the primary
site boost. Margins of 1–1.5 cm were added to the GTV
to define the CTV, taking into account the anatomic bor-
ders of the adjacent tissues and the changes in tumor bed
following surgery or chemotherapy. The PTV for the pri-
mary site boost was defined as the CTV + 0.3 cm.
The IMRT and PBT plans were prepared for all treat-
ment targets using the same CT images and structure
sets. To facilitate comparisons, the same 30.6 Gy dose
was prescribed to all PTV volumes and the treatment
plans were normalized to 100 % of the dose across 95 %
of the PTV volume. The IMRT plans were optimized
using seven coplanar beams of 6 MV that were equally
spaced around the head. The brainstem, cochlea, eye, lens,
optic nerve, optic chiasm, temporal lobe, pituitary gland,
hippocampus were included in the plan optimization as
constraint structures. The dose distribution was calculated
using the analytic anisotropic algorithm by the Eclipse
TPS with a Varian 21EX linear accelerator.
Two types of PBT were used, passively scattered pro-
ton therapy (PSPT) and spot scanning proton therapy
(SSPT). PSPT applies the spread-out Bragg peak to fit a
pristine Bragg peak to a longitudinal depth of tumor
using a range modulator. Blocks and compensators are
also used to shape the lateral beam margin and the distal
tumor shape, respectively. In PSPT planning, the block







Mixed germ cell tumor 7
PTV location and volume
Whole Ventricle (cases) 5
Mean ± SD (cc) 415.1 ± 63.6
Range (cc) 330.6–504.7
Pineal Gland (cases) 5
Mean ± SD (cc) 103.9 ± 62.5
Range (cc) 33.6–169.0
Suprasellar (cases) 5
Mean ± SD (cc) 61.3 ± 20.2
Range (cc) 44.7–87.9
Basal Ganglia (cases) 5
Left : Right 3 : 2
Mean ± SD (cc) 124.2 ± 21.3
Range (cc) 87.4–142.1
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margins were set to 0.2 cm from the PTV. Compensator
border smoothing and smearing were set to 0.8 and
0.3 cm, respectively. SSPT uses a narrow pencil beam
modulated only by transverse, longitudinal scanning
magnets in the nozzle. In our institution, the nominal
beam spot size (σ) ranges from 5.8 mm at 32 g/cm2 to
11 mm at 7.5 g/cm2 using an Ion Beam Application uni-
versal nozzle (Ion Beam Applications, Louvain-la-Neuve,
Belgium). The SSPT plans were developed using the
Eclipse TPS with an inverse planning feature in the sin-
gle field optimization mode, which optimizes dose spots
in a similar way to PSPT. In SSPT planning, a spot spa-
cing of 0.7 cm and a lateral margin of 0.7 cm were used.
The proton beam plans were calculated with the proton
convolution superposition algorithm of the Eclipse TPS.
The PSPT and SSPT plans were created using three
beams while maintaining the beam directions relative to
each other. For BG planning, posterior–anterior, anterior–
superior–oblique, and lateral beams were used through
the side on which the tumor was located. Posterior–anter-
ior and both lateral beams were used in WV plans, while
other plans were prepared using superior oblique beams
applied at equal beam angles along the midline to
minimize the dose applied to the temporal lobes.
Dosimetric comparison and statistical analysis
For all treatment plans, cumulative dose–volume histo-
grams (DVH) were exported for all structures with rela-
tive dose bins of 0.1 %. For each PTV, we calculated the
minimum, maximum, and mean dose, the minimum
doses applied to 95 and 5 % of the PTV volume (D95 %
and D5 %, respectively), the dose volume receiving more
than 100 or 50 % the prescribed dose (V100 % [pre-
scribed isodose volume] and V50 %, respectively), and
the PTV volume covered by the prescribed dose. Using
these data, we calculated the conformity index (CI),
homogeneity index (HI), gradient index (GI) and the plan
quality index (PQI) by combining CI, HI, and GI. The def-
initions of CI, HI, GI and PQI are presented in the Add-
itional file 1, available online. The ideal plan gives those
indices of 1.0. PQI is similar to the unified dosimetry
index, an efficient tool for ranking treatment plans [17].
PQI has an ideal value of 1.0 if the plan’s target volume
conforms exactly to the prescribed dose. Using the PQI,
the diversities of CI, HI, and GI in different plans can be
transferred into a single comparison index.
Of the normal structures contoured during planning,
the normal brain, both temporal lobes, both hippocampi,
and the pituitary gland were selected for analysis. The
mean doses applied to these organs were analyzed. The
volumes of normal brain that received absolute doses
of > 10 Gy or > 15 Gy were calculated. In WV irradiation,
both hippocampi were excluded from the analysisbecause of their close proximities to the target volume.
For BG tumors, the temporal lobes and hippocampi
were termed ipsilateral or contralateral depending on
the tumor’s location. The dosimetric outcomes of IMRT,
PSPT, and SSPT were compared using the Wilcoxon
signed-rank test because the sample size of our data is
small (5 cases in each set). The outcomes were consid-
ered statistically significant at p-values of < 0.05. All
statistical analyses were performed using SPSS software
version 18.0 (SPSS Inc., Chicago, IL, USA). Also, the
dose distributions are shown for a representative patient
with a WV irradiation and primary boost irradiation
planned with IMRT and PSPT technique, respectively.
Then, the sum of the WV dose and the primary site
boost were compared each other.
Results
Characteristics of the patients and the treatment targets
The patients and target volume characteristics are sum-
marized in Table 1. Of 17 patients included in this study,
10 had pure germinomas and 7 had NGGCTs. None of
the patients had disseminated disease or bifocal tumors.
The mean ± standard deviation (range) WV PTV volume
was 415.1 ± 63.6 cm3 (330.6–504.7 cm3), and varied
according to the patient’s head size and the presence of
residual hydrocephalus at the time of PBT. The PTV
volumes were 103.9 ± 62.5 cm3 (33.6–169.0 cm3), 61.3 ±
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142.1 cm3), for PG, SS and BG, respectively. The BG
tumors were located on the left side in three patients
and the right side in two patients. The median follow-up
was 18.7 months (range, 5.8–32.9 months) for 14 pa-
tients, and none of the 14 patients experienced tumor
recurrence after PBT. The follow-up data were not avail-
able for the other 3 patients.
Comparison of PTV Coverage
The results of the dosimetric comparison and statistical
analysis of PTV coverage are shown in Table 2. Regard-
ing the conformity of the PTV, the CI was better for
SSPT than both IMRT and PSPT (both p < 0.05), and
was lower for PSPT than IMRT. The GI was comparable
in PSPT and SSPT, but was better for both of these mo-
dalities than IMRT (both p = 0.043). The HI was similar
for all three modalities. The PQI decreased significantly
in the order of IMRT > PSPT > SSPT in all target loca-
tions (median, WV: 4.06, 2.89 and 2.37; PG: 4.39, 3.38
and 2.70; SS: 4.46, 3.92 and 2.49; BG: 4.45, 3.01 and
2.49). Based on the PQI—a single dosimetric index that
combines CI, GI, and HI—the PSPT and SSPT plans seem
to be superior to the IMRT plan and the SSPT plan is su-
perior to the PSPT plan in terms of PTV coverage.
Normal organ sparing
PSPT and SSPT were associated with significant reduc-





PTV CI WV 0.85 (0.72–0.88) 0.70 (0.69–0.71) 0.9
PG 0.92 (0.87–0.92) 0.83 (0.62–0.87) 0.9
SS 0.89 (0.88–0.92) 0.74 (0.72–0.83) 0.9
BG 0.88 (0.86–0.91) 0.80 (0.74–0.82) 0.9
PTV GI WV 3.30 (3.08–3.75) 1.90 (1.85–2.04) 2.1
PG 3.89 (3.47–4.62) 2.90 (2.50–3.25) 2.5
SS 3.82 (3.71–4.14) 2.78 (2.64–3.27) 2.5
BG 3.77 (3.46–4.23) 2.35 (2.18–2.57) 2.3
PTV HI WV 0.97 (0.96–0.98) 0.95 (0.94–0.95) 0.9
PG 0.96 (0.95–0.97) 0.97 (0.96–0.98) 0.9
SS 0.96 (0.95–0.97) 0.97 (0.96–0.98) 0.9
BG 0.97 (0.97–0.98) 0.97 (0.97–0.98) 0.9
PTV PQI WV 4.06 (3.82–4.73) 2.89 (2.75–3.11) 2.3
PG 4.39 (3.92–5.55) 3.38 (3.12–5.47) 2.7
SS 4.46 (4.26–4.88) 3.92 (3.62–4.05) 2.9
BG 4.45 (4.00–4.93) 3.01 (2.81–3.59) 2.4
WV whole ventricle, PG pineal gland, SS suprasellar, BG basal ganglia, PTV planning
PQI plan quality index, IMRT intensity-modulated radiation therapy, PSPT passively s
*p -value by Wilcoxon signed rank test17.5 Gy vs 22.1 Gy; PG: 8.3 Gy and 7.0 Gy vs 10.5 Gy;
SS: 4.4 Gy and 3.5 Gy vs 5.8 Gy; BG: 8.8 Gy and 7.7 Gy
vs 12.4 Gy for PSPT and SSPT vs. IMRT, respectively),
and the 10 Gy (median, WV: 77.9 and 62.7 % vs 88.5 %;
PG: 25.4 and 21.1 % vs 47.8 %; SS: 12.7 and 9.4 % vs
23.0 %; BG: 29.1 and 25.2 % vs 56.5 %) and 15 Gy dose
volumes (median, WV: 60.1 and 53.5 % vs 79.5 %; PG:
25.4 and 21.1 % vs 26.1 %; SS: 9.4 and 7.1 % vs 11.9 %;
BG: 24.3 and 20.1 % vs 33.6 %) applied to the normal
brain compared with IMRT for all four target volumes
(all p ≤ 0.05, Table 3). The dose distributions applied to
the normal brain in each target location are shown in
Fig. 1. Figure 2 shows the DVH for four treatment plans
for target volumes in four different locations. PSPT and
SSPT were associated with lower doses applied to the
normal brain for all four target locations.
The doses applied to the temporal lobe and hippocam-
pus according to the target locations are compared
among the treatment plans in Table 3. The DVH for
each plan is shown in Fig. 2. PSPT and SSPT saved sig-
nificantly greater volumes of the temporal lobes com-
pared with IMRT in all targets. PSPT and SSPT had the
greatest benefit in terms of saving the contralateral tem-
poral lobe for BG targets with median doses of 10.3 Gy
(range, 6.5–12.1 Gy) for IMRT, 0.0 Gy (range, 0.0–
0.4 Gy) for PSPT, and 0.0 Gy (range, 0.0–0.2 Gy) for
SSPT. SSPT also saved greater volumes of the temporal
lobe, even on the ipsilateral side, than PSPT (median,
15.1 Gy vs 17.0 Gy; p ≤ 0.05). In the hippocampus, PSPTge
p value*
PT IMRT vs PSPT IMRT vs SSPT PSPT vs SSPT
1 (0.89–0.92) <0.05 <0.05 <0.05
4 (0.90–0.90) <0.05 <0.05 <0.05
2 (0.90–0.94) <0.05 <0.05 <0.05
4 (0.93–0.95) <0.05 <0.05 <0.05
2 (1.99–2.19) <0.05 <0.05 <0.05
0 (2.36–3.34) <0.05 <0.05 NS
9 (2.48–2.87) <0.05 <0.05 NS
0 (2.23–2.60) <0.05 <0.05 NS
8 (0.98–0.98) <0.05 <0.05 <0.05
8 (0.97–0.98) NS <0.05 NS
7 (0.95–0.98) NS NS NS
7 (0.97–0.98) NS NS <0.05
7 (2.23–2.46) 0.043 0.043 0.043
0 (2.54–3.83) 0.043 0.043 0.043
5 (2.88–3.12) 0.043 0.043 0.043
9 (2.44–2.86) 0.043 0.043 0.043
target volume, CI conformity index, GI gradient index, HI homogeneity index,
cattered proton therapy, SSPT spot scanning proton therapy, NS not significant
Table 3 Dosimetric comparison and statistical analysis of dose to normal brain and substructures
PTV location Item Median (range, min–max), Gy p value*
IMRT PSPT SSPT IMRT vs PSPT IMRT vs SSPT PSPT vs SSPT
WV Brain - Dmean 22.1 (21.2–23.3) 19.8 (18.4–21.3) 17.5 (15.9–18.7) <0.05 <0.05 <0.05
Brain - V10Gy (%) 88.5 (85.5–90.0) 77.9 (74.8–82.1) 62.7 (55.6–66.5) <0.05 <0.05 <0.05
Brain - V15Gy (%) 79.5 (75.9–83.6) 60.1 (54.0–64.8) 53.5 (45.5–57.0) <0.05 <0.05 <0.05
Rt. Temporal 22.5 (18.6–25.8) 22.5 (18.6–25.8) 19.6 (14.8–23.7) <0.05 <0.05 <0.05
Lt. Temporal 22.4 (18.9–27.2) 22.4 (18.9–27.2) 19.4 (15.4–25.6) <0.05 <0.05 <0.05
Rt. Hippocampus 31.3 (30.4–31.6) 31.3 (30.4–31.6) 31.1 (27.4–31.2) <0.05 NS <0.05
Lt. Hippocampus 31.4 (31.2–31.5) 31.4 (31.2–31.5) 31.1 (28.7–31.2) NS <0.05 <0.05
Pituitary Gland 31.8 (30.9–31.9) 31.8 (30.9–31.9) 31.0 (30.7–31.4) NS NS NS
PG Brain - Dmean 10.5 (6.5–14) 8.3 (4.4–12.2) 7.0 (3.3–10.4) <0.05 <0.05 <0.05
Brain - V10Gy (%) 47.8 (24.1–63.9) 25.4 (13.9–42.3) 21.1 (10.2–35.8) <0.05 <0.05 NS
Brain - V15Gy (%) 26.1 (10.9–41.0) 20.5 (10.5–34.7) 16.4 (7.5–27.8) <0.05 <0.05 <0.05
Rt. Temporal 15.0 (4.8–21.2) 2.8 (0.0–10.8) 2.0 (0.0–8.8) <0.05 <0.05 NS
Lt. Temporal 14.7 (4.8–20.5) 2.9 (0.1–8.5) 3.0 (0.0–7.4) <0.05 <0.05 NS
Rt. Hippocampus 28.0 (10.9–31.2) 25.1 (6.4–31.5) 21.8 (4.8–30.9) NS <0.05 NS
Lt. Hippocampus 25.8 (15.3–30.9) 23.0 (11.0–31.5) 22.3 (8.4–30.6) NS <0.05 <0.05
Pituitary Gland 6.8 (0.7–23.5) 5.0 (0.0–29.3) 3.2 (0.0–27.7) NS NS NS
SS Brain - Dmean 5.8 (4.9–11) 4.4 (3.6–7.9) 3.5 (2.9–6.7) <0.05 <0.05 <0.05
Brain - V10Gy (%) 23.0 (18.3–49.0) 12.7 (10.2–27.1) 9.4 (7.6–22.6) <0.05 <0.05 <0.05
Brain - V15Gy (%) 11.9 (9.8–25.9) 9.4 (7.6–21.8) 7.1 (5.6–17.2) <0.05 <0.05 <0.05
Rt. Temporal 12.9 (8.8–15.8) 6.6 (4.3–9.9) 5.1 (3.4–6.9) <0.05 <0.05 <0.05
Lt. Temporal 11.9 (9.1–15.4) 6.4 (3.0–9.5) 5.0 (2.4–6.7) <0.05 <0.05 <0.05
Rt. Hippocampus 15.9 (11.7–17.5) 10.1 (4.6–16.1) 7.2 (2.4–12.6) <0.05 <0.05 <0.05
Lt. Hippocampus 16.2 (12.7–17.5) 11.0 (6.2–15.3) 7.8 (3.7–13.5) <0.05 <0.05 <0.05
Pituitary Gland 31.4 (5.9–31.6) 31.2 (15–31.4) 31.4 (14.4–32.2) NS NS NS
BG Brain - Dmean 12.4 (11.6–14.2) 8.8 (7.5–9.9) 7.7 (6.3–8.4) <0.05 <0.05 <0.05
Brain - V10Gy (%) 56.5 (52.9–66.5) 29.1 (26.5–34.1) 25.2 (22.5–28.9) <0.05 <0.05 <0.05
Brain - V15Gy (%) 33.6 (28.8–39.9) 24.3 (21.7–28.0) 20.1 (17.7–23.2) <0.05 <0.05 <0.05
Ipsilat. Temp. 19.0 (13.2–22.6) 17.0 (13.8–23.1) 15.1 (10.4–20.3) NS <0.05 <0.05
Contralat. Temp. 10.3 (6.5–12.1) 0.0 (0.0–0.4) 0.0 (0.0–0.2) <0.05 <0.05 NS
Ipsilat. Hippoc. 29.1 (24.3–31) 30.4 (27.1–31.2) 29.7 (24.6–31.1) NS NS NS
Contralat. Hippoc. 15.6 (9.2–16.7) 0.2 (0.0–0.7) 0.1 (0.0–0.6) <0.05 <0.05 NS
Pituitary Gland 12.5 (1.4–29.9) 22.4 (0.0–30) 11.5 (0.0–29.3) NS NS NS
WV whole ventricle, PG pineal gland, SS suprasellar, BG basal ganglia, PTV planning target volume, IMRT intensity-modulated radiation therapy, PSPT passively
scattered proton therapy, SSPT spot scanning proton therapy, NS not significant
*p -value by Wilcoxon’s signed rank test
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the WV and PG, but had significant benefits over IMRT
for SS and BG targets. For SS targets, the dose reduction
was greater for SSPT than IMRT and PSPT. For BG tar-
gets, the dose reduction in the hippocampus was similar
to that in the temporal lobe, suggesting greater benefits
of PSPT and SSPT in terms of saving the contralateral
hippocampus. The median doses applied to the hippo-
campus were 15.6 Gy (range, 9.2–16.7 Gy) for IMRT,
0.2 Gy (range, 0.0–0.7 Gy) for PSPT and 0.1 Gy (range,0.0–0.6 Gy) for SSPT. The dose distribution of the BG
plans shown in Fig. 1d confirms these results.
The median doses applied to the pituitary gland are
also compared in Table 3. Unlike other organs, there
were no significant benefits of PSPT and SSPT in terms
of sparing the pituitary gland. For the WV and SS targets,
the pituitary gland was included in the PTV because the
target volumes included the third ventricle and the pre-
pontine cistern. Therefore, the pituitary gland could not
be spared with any treatment plan. Although SSPT could
Fig. 1 Dose distributions of WV irradiation and PG, SS and BG tumor beds with their pre-chemotherapy MRI images. Thick pink line is WV PTV,
and thick red lines are tumor beds PTV. Prescribed dose are 30.6 Gy at 95 % volume of PTV. (a) WV (b) PG (c) SS (d) BG
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gets, IMRT offered a similar level of protection to SSPT
(median, 12.5 Gy vs 11.5 Gy; p > 0.05).
Dose distributions in a representative case
Figure 3 shows the dose distributions of a representative
case with a combined plan (WV and a tumor bed boost).
The IMRT and PSPT plans were compared using two
different prescriptions: (1) WV dose of 19.8 Gy and a
tumor bed boost of 10.8 Gy (germinoma) and (2) WV
dose of 36 Gy and a tumor bed boost of up to 55.8 Gy
(mixed germ cell tumor). PSPT saved a significant pro-
portion of the normal organs with isodose volumes of
20–70 % in combined plans comprising a WV or WB
dose and a tumor boost. In the 55.8 Gy plan, PSPT hadan apparent dose benefit over IMRT. As shown in Fig. 3c,
the 20 Gy line includes the entire brain with IMRT, but
only the 10 Gy line is marginal with PSPT.
Discussion
The radiotherapy principle for ICGCTs is to cover the
cerebrospinal fluid pathway in the brain sufficiently so
that the microscopic tumor cells located around the ven-
tricular system are fully irradiated. However, the tem-
poral lobes and the hippocampi which are important in
learning and memory receive a considerable amount of
radiation dose while performing WV and boost irradi-
ation to the tumors which are typically located along the
midline of the brain. So, they need to be protected from
irradiation as much as possible.
Fig. 2 Dose volume histogram (DVH) of normal brain and both temporal lobes in the WV, PG, SS and BG treatment plans. (a) WV (b) PG (c) SS (d) BG
Park et al. Radiation Oncology  (2015) 10:135 Page 7 of 10In a previous study, MacDonald et al. compared IMRT,
PSPT, and SSPT plans for treating pediatric ICGCTs,
and described the clinical outcomes of PSPT [18]. They
reported a superior dose distribution of SSPT over the
other planning methods, similar to our results. For tu-
mors with relatively small volumes, the normal brain
volume that receives low to intermediate radiation dose
is remarkably low in proton beam therapy compared
with the IMRT or 3D CRT. For WV targets, the dosi-
metric benefit of PBT in terms of Dmean, V10 Gy and
V15 Gy may seem less prominent because of the relatively
small volume of normal tissue outside WV in the brain.
However, for large tumors arising in other body sites
such as large retroperitoneal sarcoma or large chest wall
tumors, sparing effect of normal tissue of PBT in terms
of absolute volume of the normal tissue would be much
larger than the effect that can be observed in treatment
of brain tumors.
We found that PSPT and SSPT provided better PTV
coverage and achieved greater dose reductions for or-
gans at risk, especially the normal brain and temporal
lobes. Regarding WV irradiation with a dose of 30.6 Gy,
the 10 Gy and 15 Gy dose volumes were significantly
lower for both PBT techniques than for IMRT. When
we compared the mean doses applied to the normalbrain and temporal lobes, we found that the dose was
10 % lower for PSPT than for IMRT, and was 10 % lower
for SSPT than for PSPT. The superiority of SSPT over
PSPT is due to a lower proximal dose applied to the nor-
mal brain as a result of a lack of range modulation. The
range modulation and use of compensator is associated
with an increased normal tissue irradiation and potential
side effects such as alopecia [19, 20]. Systematic studies
are needed to examine whether this reduction in the
radiation dose translates into clinically detectable im-
provements in neurocognitive function. Previous studies
showed that when irradiating the WV, IMRT successfully
reduced the volume of the hemispheric brain volume ex-
posed to low doses, but this was achieved at the expense
of delivering an unnecessary radiation dose to the per-
iphery of the body though increased leakage radiation
[21]. Accordingly, SSPT appears to be an excellent tool
with improved conformity and reduced neutron contam-
ination compared with other radiotherapy modalities [22].
However, it should be always born in mind that SSPT
plans are more sensitive to treatment uncertainties such
as proton range uncertainty, dose calculation uncertainty,
and inter-fractional and inter-field motions compared to
PSPT. So, robust plan optimization should be considered
in SSPT plans to minimize adverse effects [23–25].
Fig. 3 Comparison of dose distribution and DVH of combined treatment plans for PG tumor bed with IMRT and PSPT. (a, c) WV 19.8 Gy + tumor
bed 10.8 Gy (b, d) WV 36 Gy + tumor bed 19.8 Gy
Park et al. Radiation Oncology  (2015) 10:135 Page 8 of 10In addition to the WV target, PBT had dosimetric ben-
efits for the other targets. The advantage of PBT in
treating SS tumors can be compared to a study of cra-
niopharyngiomas or optic gliomas arising in similar loca-
tions where reductions in low to intermediate doses
improved the intelligent quotient and academic reading
scores in a dose–cognitive model [15]. Although ICGCTs
located in the BG are infrequent, about 16 and 13 % of
germinomas and NGGCTs, respectively, were located in
the BG in patients registered between 2005 and 2011 in
the Korean ICGCT registry ((personal communication,
Chang-Ok Suh, the Korean Society for Pediatric Neuro-
Oncology)). Similar incidences were reported in Taiwan,
Hong Kong, and Japan [11, 26, 27]. Patients with tumors
located in the BG are at increased risk of reduced neuro-
cognitive function and worse performance status [11, 28,
29]. The reasons for these outcomes are complex, but the
tumor location might contribute to poor physical per-
formance because tumors in the BG can affect processing
speed and might be diagnosed much later than ICGCTs in
other locations. A radiation field with sufficient margins
around the gross tumor is needed because of the diffuse
infiltrative tumor growth in most patients. PBT signifi-
cantly reduced the dose applied to the contralateral tem-
poral lobe and the hippocampus because of the Bragg
peak phenomenon, even though the beams pass through
the ipsilateral side. In combination with WV irradiation orCSI, the dose applied to the contralateral temporal lobe
and hippocampus was reduced by 10–20 Gy for germino-
mas and NGGCTs.
We used the PQI to help compare the treatment plans
between different modalities. The CI and GI, two com-
monly used dosimetric indexes, could not precisely
depict the dose distributions of each modality. PSPT was
associated with the lowest CI because of the proximal
high-dose region around the PTV arising from the uni-
form spread-out Bragg peak. The CI was significantly
better for IMRT and SSPT than PSPT because of the
high modulation of incident radiation. However, the GI
was inferior for IMRT because of the use of multiple
beams and the high exit dose after the PTV. By contrast,
the GI for PSPT was similar to that of SSPT because of
the use of blocks and the effects of the Bragg peak.
Finally, the HI was similar for all plans. Considering
these factors, it is difficult to compare each plan and de-
termine which plan offers the best target coverage. This
highlights the need for a single dosimetric index to
compare different treatment plans, like the PQI used in
the present study. Our results suggest that PQI differen-
tiated the treatment plans more effectively than the
other indices.
The effects of brain irradiation are closely related to
the cognitive development of the brain. Merchant et al.
reported that each increase in the mean dose of 1 Gy
Park et al. Radiation Oncology  (2015) 10:135 Page 9 of 10decreases the patient’s IQ by 0.0095, 0.0092, and 0.0088
per month, when treating the total brain, left temporal
lobe, and right temporal lobe, respectively [30]. The
differences between photon and proton dosimetry in pa-
tients with an optic pathway glioma, craniopharyngioma,
and medulloblastoma were small but yielded clinically
different curves for the cognitive outcomes in a dose–
cognitive model [15]. When this model was applied to
the results of our study, the IQ deviation between IMRT
and PSPT is expected to result in IQ improvements at
70 months after treatment of 1.596, 4.077, and 4.010 at a
dose of 30.6 Gy and 3.403, 8.464, and 8.349 at a dose of
55.8 Gy for total brain, left and right temporal lobes,
respectively.
Conclusions
In conclusion, PBT provides superior tumor conformity
and normal tissue saving relative to other modalities in
the treatment of ICGCTs in various locations. Continued
follow-up and systematic assessment of neurocognitive
function is necessary for patients undergoing PBT to
evaluate whether the extent of normal tissue saving
translate into clinical benefits in children with ICGCTs.
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